VBS

VECTUS BIO FPO [VBS]
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia.
Healthcare · ASX Small Cap
$0.1850 +0.0%

Updated 31 Aug 2026 · Signals refresh every scan

⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Get alerts when VBS triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track VBS — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Trading above both moving averages — the trend is your friend here
  • Volume surging at 4.3x normal while price falls — heavy selling pressure
  • Knocking on the door of resistance — if it punches through, things could get interesting
  • On a tear — up 23.3% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.37, so it's outpacing the pack
  • Volatility is expanding fast — choppy price action, so buckle up
  • Trading above the 200-day average — the long-term trend is on your side
  • Critical cash runway (1.6 quarters)
  • 4C filed 2026-07-28
  • Very high P/S ratio (127.2x)
  • Revenue in sharp decline (-99%)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (1 events)
  • CANSLIM S: Tight float (40%)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.64%/day)
  • Liquidity risk: 6 zero-volume days in last 20
  • RBA hiking (-3pts)
  • Overseas risk_on (+2pts, S&P500 up, VIX 15)
  • Dilution risk: technical breakout with recent capital raise

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -99% — the top line is shrinking

Recent Catalysts

NONE Full Year Statutory Accounts
NONE Preliminary Final Report
NONE Cleansing Notice
LOW Quarterly Activities & Appendix 4C Cash Flow Reports

Recent ASX Announcements

2026-08-30 Full Year Statutory Accounts
2026-08-30 Preliminary Final Report PRICE SENSITIVE
2026-07-29 Cleansing Notice
2026-07-29 Application for quotation of securities - VBS
2026-07-28 Quarterly Activities & Appendix 4C Cash Flow Reports PRICE SENSITIVE

Key Metrics

$11.4M
Market Cap
8K
Avg Volume
4.3x
Vol Ratio
$0.05 — $0.46
52-Week Range
N/A
Short Interest
2 qtrs
Cash Runway
N/A
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 40%
LLeader vs LaggardpassRS: 14
IInstitutional SponsorshipweakInst: 6%
MMarket DirectionneutralNeutral

Sector: Healthcare

114 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
TRJ +24.2%GSS +18.8%IXC -15.4%BLS +15.2%RAD +11.1%
Compare:VBS vs TRJVBS vs GSSVBS vs IXC
Share this analysis

Track VBS and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required